Workflow
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Globenewswire·2025-08-18 19:30

Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US3.01,withacontingentvaluerightforpotentialadditionalaggregatepaymentsofuptoUS3.01, with a contingent value right for potential additional aggregate payments of up to US1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.Board unanimously recommends shareholders vote “FOR” the Arrangement.Shareholders are encouraged to review the circular carefully ...